title: Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
authors.affiliation: Department of Hematological Malignancies, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA. prebett@ipc.unicancer.fr.
authors.forename: Thomas
authors.initials: T
authors.lastname: Prébet
authors.forename: Sylvain
authors.initials: S
authors.lastname: Thepot
authors.forename: Steven D
authors.initials: SD
authors.lastname: Gore
authors.forename: François
authors.initials: F
authors.lastname: Dreyfus
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D017211:Treatment Failure
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine